Informational only — Not medical advice. Always consult a licensed healthcare provider.

MedBD
বাং
Community data Updated 2 months ago

Dydrogesterone

Female Sex hormones Prescription
Check interactions
🌐 বাংলায় দেখুন

Indications

Menstrual Disorder

Caryon tablet is indicated for progesterone deficiencies, including treatment of threatened miscarriage, treatment of habitual miscarriage, treatment of dysmenorrhoea, treatment of endometriosis, treatment of secondary amenorrhoea, treatment of irregular cycles, treatment of dysfunctional uterine bleeding, and treatment of infertility due to luteal insufficiency, as well as luteal support as part of an Assisted Reproductive Technology (ART) programme. It is also indicated for Hormone Replacement Therapy, to counteract the effects of unopposed oestrogen on the endometrium in women with an intact uterus undergoing hormone replacement therapy for disorders arising from natural or surgically induced menopause.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Dydrogesterone is an orally active progestogen. In an estrogen-primed uterus, it brings the endometrium to a full secretory state, which guards against the endometrial hyperplasia and malignant change that estrogen alone can cause. It is used in all forms of endogenous progesterone deficiency. It carries no estrogenic, androgenic, thermogenic, anabolic, or corticoid activity.

Pregnancy & Breastfeeding

Dydrogesterone has not so far been linked to any harmful effects when used during pregnancy. It does, however, pass into breast milk, and because a risk to the nursing infant cannot be ruled out, it should not be used while breast-feeding. As for fertility, there is no evidence that Dydrogesterone reduces it.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Progesterone deficiencies: Threatened miscarriage: 40 mg (four tablets) at once, then 10 mg (one tablet) every eight hours until symptoms remit. Habitual miscarriage: 10 mg (one tablet) twice daily until the twentieth week of pregnancy. Dysmenorrhoea: 10 mg (one tablet) twice daily from day 5 to day 25 of the menstrual cycle. Endometriosis: 10 mg (one tablet) two or three times daily from day 5 to day 25 of the cycle or continuously. Dysfunctional bleeding (to arrest bleeding): 10 mg (one tablet) twice daily for five to seven days. Presentation should be given with oestrogen. Dysfunctional bleeding (to prevent bleeding): 10 mg (one tablet) twice daily from day 11 to day 25 of the cycle. Presentation should be given with oestrogen. Amenorrhoea: An oestrogen once daily from day 1 to day 25 of the cycle, together with 10 mg Presentation twice daily from day 11 to day 25 of the cycle. Irregular cycles: 10 mg (one tablet) twice daily from day 11 to day 25 of the cycle. Infertility due to luteal insufficiency: 10 mg (one tablet) daily from day 14 to day 25 of the cycle. The treatment should be continued for at least 6 consecutive cycles. It is advisable to continue this treatment during the first month of any pregnancy using the doses stated with respect to habitual miscarriage. Luteal support as part of an Assisted Reproductive Technology (ART) treatment: 10 mg three times daily (three tablets daily) starting at the day of oocyte retrieval and continuing for 10 weeks if pregnancy is confirmed. Hormone Replacement Therapy: In combination with continuous oestrogentherapy, take one tablet daily for 14 consecutive days of a 28 day cycle. In combination with cyclical oestrogen therapy take one tablet daily during the last 12 to 14 days of oestrogen therapy. For doctors: If endometrial biopsies or ultrasound reveal inadequate Presentationational response, 20 mg Dydrogesterone should be prescribed. For patients: If you are not sure what type of oestrogen therapy you are on, talk to your Doctor before taking Presentation. There is no relevant use of Dydrogesterone before menarche. The safety and efficacy of Dydrogesterone in adolescents aged 12 to 18 years has not been established.